Emedastine

Emedastine

SCHEMBL4802530

CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH1

The experimentally established mechanism targets of Emedastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Emedastine SCHEMBL29493445 0.99
Emedastine SCHEMBL29770 0.99
Emedastine SCHEMBL28369975 0.98
SCHEMBL10922792 0.94
SCHEMBL7655663 0.94
SCHEMBL10925460 0.91
Emedastine SCHEMBL5322530 0.91
Emedastine SCHEMBL449581 0.90 POLB (0.62)
Emedastine SCHEMBL41385 0.90 POLB (0.62)
Emedastine SCHEMBL449580 0.90 POLB (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112585690-A System and method for producing individualized individual unit doses containing a pharmaceutically active substance 阿奎斯蒂弗医疗股份有限公司 2021-03-30 CN disclosed
US-7348140-B1 Clinical indications for genotyping polymorphic variants of G-protein coupled receptors ACADIA PHARMACEUTICALS, INC. (US) 2008-03-25 US disclosed
US-6245795-B1 USING HISTAMINE H2 RECEPTOR ANTAGONIST KANEBO, LIMITED (JP) 2001-06-12 US disclosed